Use one universal, automated protocol for robust sequencing across applications.
Analyze SNVs, Indels, CNVs, ITDs, PTDs, and gene fusions with confidence.
Match cancer genomic profiles to the most up-to date information with OncoPortal™ Knowledge Base.
Quickly prepare comprehensive reports adapted to your needs.
Sensitive SNV and Indel detection
Accurate CNV calling
Partner‑agnostic fusion detection
Precise molecular barcoding
Robust variant annotation
SOPHiA DDM™ Community Myeloid Solution | SOPHiA DDM™ Extended Myeloid Plus Solution (ExtMYS+) | SOPHiA DDM™ Community Myeloid Plus Solution 51 genes (CMYS-51+) | SOPHiA DDM™ Dx Myeloid Solution (DxMYS) | |
---|---|---|---|---|
No. genes | 94 genes, full CDS | 98 genes, full CDS | 51 genes, 28 full CDS | 30 genes, 10 full CDS |
Fusion calling | 28 genes (∞ fusion partners) | 118 fusion pairs (predefined fusion partners) | 118 fusion pairs (predefined fusion partners) | Not available |
Sample Type | Blood and bone marrow | Blood and bone marrow | Blood and bone marrow | Blood |
Recommended Input Amount | 50 ng DNA | 50 ng DNA + 500 ng RNA | 50 ng DNA + 500 ng RNA | 200 ng DNA |
Sequencer Compatibility | Illumina NextSeq® | Illumina NextSeq® | Illumina MiniSeq® Illumina MiSeq® Illumina NextSeq® | Illumina MiSeq® (for CE-IVD purposes) |
Detected Variants & Biomarkers | • SNVs | • SNVs • Indels • CNVs • FLT3 IDTs • KMT2A PDTs • RNA gene fusions | • SNVs • Indels • CNVs • FLT3 IDTs • KMT2A PDTs • RNA gene fusions | • SNVs • Indels • CNVs • FLT3 IDTs |
SOPHiA DDM™ Community Myeloid Solution
SOPHiA DDM™ Community Myeloid Solution
SOPHiA DDM™ Community Myeloid Solution 51 genes (CMYS-51)
SOPHiA DDM™ Extended Myeloid Solution (ExtMYS)
SOPHiA DDM™ Dx Myeloid Solution (CE-UVD)
SOPHiA DDM™ Myeloid Solution (MYS)
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.